Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.
Clinical Trials
1
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
Recruiting
1
100.0%
No approval data available
- Tempus AI announced a definitive agreement to acquire cancer test maker Personalis in a deal valued at approximately $1.5 billion, paid primarily in Tempus stock. - The acquisition centers on Personalis' NeXT Personal test, which uses minimal residual disease (MRD) technology to detect trace amounts of cancer after treatment via personalized genetic signatures. - Personalis shareholders will receive $16.25 per share, representing a 5.6% premium to the last closing price, with Tempus retaining the option to pay up to 50% in cash. - The deal builds on an existing partnership from November 2023 and is expected to close in late 2026 or early 2027, according to Tempus CEO Eric Lefkofsky.
- Personalis published two studies showing their NeXT Personal test can detect circulating tumor DNA at ultrasensitive levels across 24 different cancer types, with 98% detection rate at baseline. - The test identified molecular response to immunotherapy a median of 23 days after treatment initiation and detected disease progression 161 days before imaging in advanced cancer patients. - Patients achieving durable molecular clearance had 100% overall survival, while those with early ctDNA increases had zero percent overall response rate to immunotherapy. - The ultrasensitive range detection proved critical, with 33% of positive ctDNA detections occurring below 100 PPM in advanced tumors where higher sensitivity tests might miss these signals.
- Personalis and academic collaborators will showcase new clinical data on their ultrasensitive NeXT Personal ctDNA assay at upcoming AACR and ASCO conferences, demonstrating its application across multiple cancer types. - The VICTORI study will present preliminary results on post-surgical minimal residual disease detection in colorectal cancer, while the TRACERx collaboration will share findings from one of the largest ctDNA studies in early-stage lung cancer. - New research will expand clinical evidence for NeXT Personal into neoadjuvant treatment settings for breast cancer and cervical cancer, supporting the company's mission to enable earlier detection of residual and recurrent cancer.
- A new ultrasensitive ctDNA test, NeXT Personal, shows promise in predicting lung cancer relapse risk and overall survival in early-stage patients. - The test, which detects circulating tumor DNA in blood, identified patients with low ctDNA levels who were less likely to relapse after surgery. - High sensitivity of NeXT Personal allowed for the detection of smaller amounts of ctDNA, improving the accuracy of risk stratification. - The findings suggest ctDNA testing could inform treatment decisions and personalize care for early-stage lung cancer patients.
- A new ultra-sensitive liquid biopsy using whole genome sequencing can detect breast cancer recurrence an average of 15 months before clinical symptoms appear, with the longest lead time reaching 41 months. - The test successfully identified all 11 patients who relapsed during a five-year trial by detecting circulating tumor DNA (ctDNA) in blood samples, with no false negatives among 60 patients who remained cancer-free. - This breakthrough technology analyzes up to 1,800 mutations compared to conventional tests that examine only 16-50 mutations, making it significantly more sensitive for early detection. - The findings could enable earlier intervention strategies for high-risk breast cancer patients, potentially improving treatment outcomes before cancer spreads to other parts of the body.
